Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
NCT ID: NCT05583019
Last Updated: 2023-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
88 participants
OBSERVATIONAL
2022-10-27
2023-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Relevance of Scratching and Sleep in Atopic Dermatitis
NCT05467046
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy
NCT03090178
Scratch and Sleep Quantification in Atopic Dermatitis
NCT03490877
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
NCT05200403
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
NCT05235724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will begin with an initial in-laboratory intake appointment to verify study eligibility to participate in the study. We do our best to screen for study eligibility over the phone, but there are some eligibility requirements that must be assessed in person. This means that at the first appointment, there is a chance that the prospective participant will not be eligible to continue with the remainder of study activities. In the event that they are not eligible to continue at the first in- person appointment, they will be compensated a prorated study amount for their time.
Following the initial intake appointment, the participant will sleep overnight at the sleep laboratory/hotel. The participant will wear both the Apple Watch and the CentrePoint Insights Watch (CPIW) wrist devices, one of each, on both wrists. They will be asked to don the devices at least 6 hours before bedtime on the first overnight visit (day 1) and wear devices continuously (as specified) thereafter. The participant will be video recorded with an infra-red thermal camera (this video is de-identified, and only shows a heat map of their body, so facial features cannot be seen) during the sleep laboratory/hotel visits, wear the wrist accelerometry devices, and complete electronic questionnaires. In addition, on the second overnight in the sleep lab they will also have sensors placed on their head and limbs to monitor their sleep. Both nights, all three devices will also be next to the participant on the night stand, collecting information about their surroundings while they sleep. Upon the completion of the second night in the sleep laboratory (Days 1 and 2), they will then continue to wear wrist accelerometry devices and complete Patient Reported Outcome (PRO) questionnaires at home. The participants will be split into two cohorts (groups): Cohort 1 will wear both the CPIW and the GENEActiv device on both wrists and Cohort 2 will wear both the Apple Watch and GENEActiv device on both wrists. The participants will return to the laboratory on day 8 (+/- 2 days) to swap out devices. Cohort 1 will then wear both the Apple Watch and the GENEActiv device on both wrists and Cohort 2 will wear both the CPIW and GENEActiv device on both wrists for the remaining study days. At the conclusion of the at-home portion of the study, the participant will return the devices and assessments to the laboratory and complete final assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Control
Those who do not have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Clear (0) or Almost Clear (1) on the Investigator's Static Global Assessment (ISGA) at intake.
GENEActiv Accelerometry Device
a watch like wearable sensor
Centrepoint Insights Watch (CPIW) Accelerometry Device
a watch like wearable sensor
Apple Watch Accelerometry Device
a watch like wearable sensor
Polysomnography
Sleep monitor
Videography
Thermal Camera
Mild Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Mild (2) on the Investigator's Static Global Assessment (ISGA) at intake.
GENEActiv Accelerometry Device
a watch like wearable sensor
Centrepoint Insights Watch (CPIW) Accelerometry Device
a watch like wearable sensor
Apple Watch Accelerometry Device
a watch like wearable sensor
Polysomnography
Sleep monitor
Videography
Thermal Camera
Moderate Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Moderate (3) on the Investigator's Static Global Assessment (ISGA) at intake.
GENEActiv Accelerometry Device
a watch like wearable sensor
Centrepoint Insights Watch (CPIW) Accelerometry Device
a watch like wearable sensor
Apple Watch Accelerometry Device
a watch like wearable sensor
Polysomnography
Sleep monitor
Videography
Thermal Camera
Severe Atopic Dermatitis (AD)
Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Severe (4) on the Investigator's Static Global Assessment (ISGA) at intake.
GENEActiv Accelerometry Device
a watch like wearable sensor
Centrepoint Insights Watch (CPIW) Accelerometry Device
a watch like wearable sensor
Apple Watch Accelerometry Device
a watch like wearable sensor
Polysomnography
Sleep monitor
Videography
Thermal Camera
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GENEActiv Accelerometry Device
a watch like wearable sensor
Centrepoint Insights Watch (CPIW) Accelerometry Device
a watch like wearable sensor
Apple Watch Accelerometry Device
a watch like wearable sensor
Polysomnography
Sleep monitor
Videography
Thermal Camera
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participants aged ≥12 years of age and \<75 years of age at Day 1.
2. Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable).
3. Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures.
4. Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed)
5. Have a clinical diagnosis of AD according to the criteria of Hanifin and Rajka (concomitant AD treatments are permitted on study).
6. Have AD involvement ≥ 5% Treatable % Body Surface Area (BSA) excluding the scalp.
7. Have an Investigator's Static Global Assessment (ISGA) score of Mild (2), Moderate (3) or Severe (4) at the screening visit within 14 days of study enrollment.
8. Have a minimum Peak Pruritus Numerical Rating Scale (PP-NRS) assessment score of 3 (out of 10).
9. Wide Range Achievement Test-4 (WRAT-4) Word Reading Subtest equivalent to 8th grade reading level or greater (for ages ≥18 years only).
Healthy (non-AD) Participants:
1. Participants aged ≥12 years of age and \<75 years of age at Day 1.
2. Written informed consent from participant or parent(s)/guardian(s) and assent from the participant (where assent is applicable).
3. Participant (and parent(s)/guardian(s)) are willing and able to comply with study instructions, study visits, and procedures.
4. Native English speakers or demonstrated fluency in English (participant; and parent(s)/guardian(s) as needed)
5. Does not have suspected or confirmed clinical diagnosis of AD (according to the criteria of Hanifin and Rajka).
6. Have an ISGA score of Clear (0) or Almost Clear (1) at the screening visit within 14 days of study enrollment.
7. WRAT-4 Word Reading Subtest equivalent to 8th grade reading level or greater (for ages ≥18 years only).
Exclusion Criteria
1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent non-AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities.
2. Allergy to polyurethane resin (strap/wristband component).
3. Has documented non-AD related insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder).
4. AD affected surface areas are in a location of device placement.
5. If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months.
6. Has unstable AD (Total BSA\>40%).
7. Has a significant active systemic or localized infection, including actively infected AD.
8. Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study for AD.
9. Has any planned surgical or medical procedure that would overlap with study participation.
10. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study.
11. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21).
12. Is a female who is breastfeeding or pregnant, as disclosed by the participant.
13. Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period.
14. Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices.
Healthy (non-AD) Participants:
1. Has any clinically significant medical disorder, condition, disease (including any active/potentially recurrent dermatological conditions (such as Netherton syndrome) or clinically significant finding at screening that precludes participant's participation in study activities.
2. Allergy to polyurethane resin (strap/wristband component).
3. Has documented clinically diagnosed insomnia, sleep apnea or other sleep-related disorders (e.g., narcolepsy, restless legs syndrome, circadian rhythm disorder).
4. If participant has a history of angioedema or anaphylaxis and has had any anaphylactic reactions within the past 6 months.
5. Has recently (within 30 days of Day 1) participated in or is currently involved in another drug or device research study.
6. Has any planned surgical or medical procedure that would overlap with study participation.
7. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees directly involved in the conduct of the study.
8. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard liquor) within 6 months of baseline as disclosed by participant during evaluation (for those participants over the age of 21).
9. Is a female who is breastfeeding or pregnant, as disclosed by the participant.
10. Current shift worker or travel across more than two time zones in the past 2 weeks, and/or during the study period.
11. Participants with cardiac pacemakers, electronic pumps or any other implanted medical devices.
12 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SymmetryScience Group, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark B Moss, PhD
Role: PRINCIPAL_INVESTIGATOR
SymmetryScience Group, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hampton Inn & Suites
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSG0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.